Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Expert Rev Pharmacoecon Outcomes Res
; 24(2): 217-225, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38149409
ABSTRACT
OBJECTIVE:
To assess the cost-effectiveness of sacituzumab govitecan for treating relapsed or refractory metastatic triple-negative breast cancer (TNBC) in Singapore.METHODS:
A three-state partitioned survival model was developed to evaluate the cost-effectiveness of sacituzumab govitecan from a healthcare system perspective over 5 years. Clinical inputs were obtained from the ASCENT trial. Health state utilities were retrieved from the literature and direct costs were sourced from public healthcare institutions in Singapore. Sensitivity and scenario analyses were conducted to explore the impact of uncertainties and assumptions on cost-effectiveness results.RESULTS:
Compared with single-agent chemotherapy, sacituzumab govitecan was associated with a base-case incremental cost-effectiveness ratio (ICER) of S$328,000 (US$237,816) per quality-adjusted life year (QALY) gained. One-way sensitivity analyses showed that the ICER was most sensitive to the cost of sacituzumab govitecan and progression-free utility values. Regardless of variation in these parameters, the ICER remained high, and a substantial price reduction was required to reduce the ICER.CONCLUSION:
At its current price, sacituzumab govitecan does not represent a cost-effective treatment for relapsed or refractory metastatic TNBC in Singapore. Our findings will be useful to inform funding decisions alongside other factors including clinical effectiveness, safety, and budget impact considerations.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Camptotecina
/
Inmunoconjugados
/
Anticuerpos Monoclonales Humanizados
/
Neoplasias de la Mama Triple Negativas
/
Antineoplásicos
Límite:
Humans
País como asunto:
Asia
Idioma:
En
Año:
2024
Tipo del documento:
Article